Vaccine clinical trials for ovarian cancer

Gynecol Oncol ; 2 : — Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol ; 3 11 : — The three Es of cancer immunoediting. Annu Rev Immunol ; 22 : — The immunobiology of cancer immunosurveillance and immunoediting. Immunity ; 21 2 : — Blood ; 3 : — Efficacy of levomethyl tryptophan and dextromethyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res ; 69 13 : — Cancer Immunol Immunother April 25 [epub ahead of print], doi Oncotarget ; 6 29 : — Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.

Oncotarget ; 6 13 : — Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol ; 33 34 : — Avelumab MSBC , an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial. J Clin Oncol ; 33 Suppl : Antitumor activity and safety of pembrolizumab in patients pts with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.

Old LJ. Cancer Immun ; 1: 1. Nat Rev Cancer ; 5 8 : — Cancer Res ; 63 18 : — NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.

Gynecol Oncol ; 3 : — Cancer Immunol Res ; 1 5 : — Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Cancer Immunol Res ; 2 1 : 37— J Clin Oncol ; 31 17 : — PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature ; : — Exploiting the mutanome for tumor vaccination. Cancer Res ; 72 5 : — Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.

J Exp Med ; 11 : — Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res ; 20 5 : — Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Science ; : — Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med ; 10 : — Nat Med ; 21 1 : 81— Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res ; 20 13 : — Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.

Curr Opin Immunol ; 18 2 : — The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol ; 11 : — Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med ; 10 9 : — In vivo targeting of antigens to maturing dendritic cells via the DEC receptor improves T cell vaccination.

J Exp Med ; 6 : — A phase I clinical trial of adoptive T cell therapy using IL secreting MUC ecto directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med ; 13 : IL secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology ; 4 3 : e Tumor-targeted T cells modified to secrete IL eradicate systemic tumors without need for prior conditioning. Blood ; 18 : — ILsecreting CDtargeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.

Leukemia ; 29 2 : — Driving CAR T-cells forward. Nat Rev Clin Oncol ; 13 6 : — Development of CAR T cells designed to improve antitumor efficacy and safety.

Pharmacol Ther ; doi The purpose of the study is to determine the best dose of CC oral azacitidine combined with pembrolizumab for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as glutathione, may help prevent peripheral neuropathy caused by paclitaxel and carboplatin.

It is not yet known whether glutathione is more effective than a placebo in preventing peripheral neuropathy. The purpose of this study is to evaluate the safety and effectiveness of combined treatment with niraparib and pembrolizumab MK in patients who have triple-negative breast cancer that is advanced or has spread, or ovarian cancer that has returned after previous treatment.

This pilot clinical trial studies the safety and immunogenicity of vaccine therapy in treating patients with stage IIIC-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer following surgery and chemotherapy. Vaccines made from a person's peptide treated white blood cells may help the body build an effective immune response to kill tumor cells.

This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a day cycle.

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent.

Niraparib or placebo in a ratio will be administered once daily continuously during a day cycle. Safety and The purpose of this study is to evaluate the safety and tolerability, as well as some activity parameters, of TG in patients with ovarian, fallopian or peritoneal serous carcinoma. This randomized phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back.

Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin The purpose of this study is to evaluate the response to treatment with Ribociclib and Letrozole in patients with low-grade serous cancer of the ovary, fallopian tube or peritoneum.

The purpose of this study is to assemble a collection of serial plasma biospecimens from women with ovarian, primary peritoneal, or fallopian tube cancer for future research projects to identify changes in levels of various plasma components that occur during the course of ovarian cancer, including changes that occur with debulking surgery, chemotherapy, disease relapse, and subsequent therapy. This is a Phase 1 multi-center study to evaluate the clinical safety and immune response of ID-LV when injected intradermally in patients with advanced cancer.

ID-LV is a novel immunotherapy agent designed to target dendritic cells and stimulate the body's immune system to fight the spread and growth of cancer for patients whose tumors express the NY-ESO-1 protein. Patients with melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1 may be considered for the trial. Selected sites will be evaluating ID-LV with pembrolizumab for patients with melanoma who have inadequately responded to anti-PD-1 therapy.

This study is a double-blind, randomized, placebo-controlled niraparib:placebo study in patients with Stage III or IV ovarian cancer. The study will assess the efficacy of niraparib as maintenance treatment, as measured by PFS. This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer.

Risk reducing salpingo oophorectomy RRSO is surgery to remove the fallopian tubes and ovaries at the same time. Interval salpingectomy with delayed oophorectomy ISDO is surgery to remove the fallopian tubes. It is not known whether ISDO works better than RRSO at lowering risk of ovarian cancer and improving the sexual function and psychosocial well-being in patients with genetic mutation.

The purpose of this study is to characterize the microbiome in the genital tract and in the peritoneal cavity of subjects with ovarian, fallopian tube, and primary peritoneal cancer. The purpose of this study is to test an experimental combination of two drugs, ABT and Cyclophosphamide CP , which we hope may eventually lead to promising new therapies for cancer.

This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Metformin hydrochloride may help carboplatin, paclitaxel and docetaxel work better by making tumor cells more sensitive to the drugs. Studying samples of blood and tissue in the laboratory from patients receiving metformin hydrochloride may help doctors This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.

Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.

Some block the ability of tumor cells to grow and spread. The purpose of this study is to compare the effectiveness and safety of mirvetuximab soravtansine vs.

Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. This is a double-blind, randomized, Phase II trial. Patients with advanced ovarian cancer that has not progressed following completion of standard-of-care chemotherapy are eligible to participate.

Treatment will be administered as a consolidation therapy beginning within one year of the last administration of platinum. Effective treatments for recurrent gynecological cancer are lacking, and there is a need for novel therapeutic options.

One of the barriers to improving outcomes in this subgroup of patients is the paucity of tumor models that can mimic patient characteristics to study novel therapies. Patient-derived xenograft PDX models are considerate the most representative pre-clinical model of human cancer, recapitulating the key characteristics of the original patient tumor.

Other preclincal models to test drug effcicacy includes ex vivo 3D culture and 2D culture systems. In this study, we make and test preclinical models of gynecological cancers ovarian, fallopian tube, peritoneal, uterine, The purpose of this study is to create and maintain a resource of biospecimens and annotated clinical data for research projects focused on ovarian cancer.

Individuals who are undergoing evaluation for a pelvic mass are recruited, as well as age-matched community controls who have never had ovarian, primary peritoneal or fallopian tube cancer. This randomized pilot phase II trial studies how well serum bovine immunoglobulin protein isolate works in improving quality of life and post-operative recovery in patients with gynecological cancer after undergoing surgery.

Serum bovine immunoglobulin supplementation may improve the quality of life of patients with gynecological cancer. This is a two-part study consisting of Part A dose regimen finding followed by Part B dose expansion. Part A dose regimen finding will allow definition of the maximum tolerated dose MTD through dose escalation and possible dose interval modification. The purpose of this study is to evaluate TST, a recombinant humanized anti-Claudin This study is being done to gather information.

The study will provide important information related to the safety and the effect of the vaccine on a patient's immune system. What researchers learn from this study could possibly be used in the future to prevent or delay recurrence of breast or ovarian cancers. This phase II trial studies how well ribociclib and letrozole work in treating patients with estrogen receptor ER positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer that has returned come back after a period of improvement.

Ribociclib may stop the growth of tumor cells by blocking some enzymes needed for cell growth. Cancer cells that are estrogen receptor positive may need estrogen to grow. Letrozole lowers the amount of estrogen made by the body and this may stop the growth of tumor cells that need estrogen to grow.

Giving ribociclib together with letrozole may be an effective treatment in This is a Phase I study to understand the biodistribution of MM and to determine the feasibility of using Ferumoxytol as a tumor imaging agent. The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB in subjects with advanced hepatocellular carcinoma and other malignancies.

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics PK , and biological activity of escalating doses of ATRC, an engineered, fully human immunoglobulin G, subclass 1 IgG1 antibody derived from a naturally-occurring human antibody. This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery or ovarian, fallopian tube, primary peritoneal, or triple-negative breast cancer that has come back.

Research continues in the development of a number of vaccines designed to prevent the recurrence of ovarian cancer. Ovarian cancer vaccines are available only in clinical trials.

Ovarian cancer vaccines are a type of immunotherapy, which is treatment that harnesses the body's germ-fighting immune system to attack cancer cells. Researchers hope to use ovarian vaccines to train the immune system cells to detect and attack any cancer cells that reappear after initial treatment has been completed.

Surgery followed by chemotherapy remains the standard primary treatment for ovarian cancer. Researchers also are studying how cancer vaccines are best used in combination with chemotherapy and other treatments, including other immunotherapies. Although research has shown that ovarian cancer vaccines may hold promise, these studies have involved only small numbers of participants.

More and larger studies are needed to further evaluate the potential role that vaccines may play in preventing recurrent ovarian cancer. If you're interested in participating in a clinical trial studying ovarian cancer vaccines, discuss it with your doctor. Your doctor can help you evaluate the options and determine whether a clinical trial is appropriate for your specific situation. Timothy J. Moynihan, M. There is a problem with information submitted for this request. Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID, plus expertise on managing health.

Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you.

If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices.